Marker or Factor (cutoff)^{*} | No. of interpretable cases | Significance (P value) | |
---|---|---|---|
1 | PR (score 0 vs. 1, 2, and 3) | 357 | P = 0.007, positive factor |
2 | ER (score 0 vs. 1, 2, and 3) | 324 | P = 0.005, positive factor |
3 | HER2 (score 0 and 1 vs. 3) | 337 | P = 0.03, negative factor |
4 | p53 (score 0 vs. 1 and 3) | 309 | P = 0.001, negative factor |
5 | Her3 (scores 0 and 1 vs. 2 and 3) | 278 | P = 0.01, negative factor |
6 | Cox2 (scores 0 and 1 vs. 2 and 3) | 356 | P = 0.003, negative factor |
7 | NSE (score 0 vs. 1, 2, and 3) | 335 | P = 0.04, positive factor |
8 | Relaxin (score 0 vs. 1, 2, and 3) | 361 | P = 0.02,^{†} positive factor |
9 | Ki67 (score 0 vs. 1, 2, and 3) | 319 | P = 0.02, negative factor |
10 | CA IX (score 0 vs. 1 and 2) | 322 | P = 0.05, negative factor |
11 | TIP1(scores 0, 1, and 2 vs. 3) | 272 | P = 0.01, negative factor |
12 | PTEN(scores 0 vs. 1, 2, and 3) | 344 | P = 0.003,^{†} positive factor |
13 | IGFBP2 (scores 0 and 1 vs. 2 and 3) | 301 | P = 0.04, negative factor |
14 | IGFBP5(scores 0 and 1 vs. 2 and 3) | 301 | P = 0.05, negative factor |
15 | Mast cell (CD117) (score 0 vs. 1) | 346 | P = 0.003, positive factor |
16 | CD10 (scores 0, 1, and 2 vs. 3) | 300 | P = 0.008, negative factor |
17 | YB1 (scores 0, 1, and 2 vs. 3) | 305 | P = 0.01, negative factor |
18 | CD68 (scores 0 and 1 vs. 2 and 3) | 331 | NS (P = 0.074) |
19 | HSP27(score 0 vs. 1, 2, and 3) | 300 | NS (P = 0.14) |
20 | p63 (score 0 vs. 1, 2, and 3) | 376 | NS (P = 0.2) |
21 | CK5/6 (score 0 vs. 1, 2, and 3) | 350 | NS (P = 0.06) |
22 | Lymph node metastasis | 392 | P < 0.0001, negative factor |
23 | Tumor size | 366 | P < 0.0001, negative factor |
24 | Tumor grade | 438 | NS (P = 0.08), negative factor |
25 | Cluster groups based on 21 markers^{‡} | 281 | NS (P = 0.15) |
26 | Cluster groups based on 20 markers^{‡} | 277 | P = 0.0025 |
27 | Cluster groups based on 19 markers | 267 | P = 0.0003^{‡} (P = 0.0014)^{§} |
28 | Cluster groups based on 18 markers^{‡} | 272 | P = 0.0012 |
29 | Cluster groups based on 17 markers^{‡} | 273 | NS (P = 0.18) |
30 | Cluster groups based on 11 markers^{‡} | 294 | P < 0.0001 (P = 0.0001)^{§} |
Abbreviations: NS, nonsignificant (P > 0.05); NSE, neuron-specific enolase.
* Survival analysis was done on binary data using the cutoff points identified.
† Reached significance in node-negative subset of patients only; P < 0.2 for all patients.
‡ Cluster group 1 versus 2 and 3.
§ Cluster group 1 versus 2 versus 3.